Lavinia Fabeni
Lavinia Fabeni
Verified email at
Cited by
Cited by
Characterization and structural analysis of HIV-1 integrase conservation
F Ceccherini-Silberstein, I Malet, R D'Arrigo, A Antinori, AG Marcelin, ...
AIDS Rev 11 (1), 17-29, 2009
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing
D Armenia, I Vandenbroucke, L Fabeni, H Van Marck, V Cento, R D’Arrigo, ...
Journal of Infectious Diseases 205 (4), 557-567, 2012
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels
MM Santoro, L Fabeni, D Armenia, C Alteri, D Di Pinto, F Forbici, A Bertoli, ...
Clinical infectious diseases 58 (8), 1156-1164, 2014
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors
F Ceccherini-Silberstein, I Malet, L Fabeni, S Dimonte, V Svicher, ...
Journal of antimicrobial chemotherapy 65 (11), 2305-2318, 2010
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group
V Svicher, R D'Arrigo, C Alteri, M Andreoni, G Angarano, A Antinori, ...
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors
F Ceccherini-Silberstein, K Van Baelen, D Armenia, M Trignetti, ...
Antimicrobial agents and chemotherapy 54 (9), 3938-3948, 2010
Impact of pre-therapy viral load on virological response to modern first-line HAART
MM Santoro, D Armenia, C Alteri, P Flandre, A Calcagno, C Gori, L Fabeni, ...
International Medical Press 18 (7), 867-876, 2013
Performance evaluation of the COBAS/TaqMan HIV-1 v2. 0 in HIV-1 positive patients with low viral load: a comparative study
P Paba, L Fabeni, M Ciccozzi, CF Perno, M Ciotti
Journal of virological methods 173 (2), 399-402, 2011
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group
C Alteri, M Montano, R D'Arrigo, M Andreoni, G Angarano, A Antinori, ...
Edizioni Internazionali 35 (1), 17-25, 2012
Specific mutations related to resistance to HIV-1 integrase inhibitors are associated with reverse transcriptase mutations in HAART-treated patients
F Ceccherini-Silberstein, I Malet, L Fabeni, V Svicher, C Gori, S Dimonte, ...
Antiviral Therapy 12, S6-S6, 2007
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients
MM Santoro, D Armenia, L Fabeni, M Santoro, C Gori, F Forbici, V Svicher, ...
Clinical Microbiology and Infection 18 (8), E289-E298, 2012
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA
M Zaccarelli, MM Santoro, D Armenia, V Borghi, W Gennari, C Gori, ...
Journal of Clinical Virology 82, 94-100, 2016
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages andá…
M Pollicita, M Surdo, F Di Santo, MF Cortese, L Fabeni, V Fedele, I Malet, ...
Journal of Antimicrobial Chemotherapy 69 (9), 2412-2419, 2014
Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy
MM Santoro, C Alteri, L Ronga, P Flandre, L Fabeni, F Mercurio, ...
AIDS research and human retroviruses 28 (10), 1285-1293, 2012
HIV-1 drug resistance in recently HIV-infected pregnant mother’s na´ve to antiretroviral therapy in Dodoma urban, Tanzania
F Vairo, E Nicastri, G Liuzzi, Z Chaula, B Nguhuni, N Bevilacqua, F Forbici, ...
BMC infectious diseases 13 (1), 439, 2013
Genetic diversity of HIV type 1 in Montenegro
M Ciccozzi, D Vujošević, A Lo Presti, B Mugoša, Z Vratnica, A Lai, ...
AIDS research and human retroviruses 27 (8), 921-924, 2011
Virological response and resistance in multi-experienced patients treated with raltegravir
F Ceccherini-Silberstein, D Armenia, R D'Arrigo, V Micheli, L Fabeni, ...
ANTIVIRAL THERAPY 13 (4), A20-A20, 2008
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia
D Armenia, L Fabeni, C Alteri, D Di Pinto, D Di Carlo, A Bertoli, C Gori, ...
Journal of Antimicrobial Chemotherapy 70 (6), 1865-1873, 2015
Performance evaluation of the Artus hepatitis C virus QS-RGQ assay
P Paba, L Fabeni, CF Perno, M Ciotti
Journal of virological methods 179 (1), 77-80, 2012
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and-treated patients
I Malet, M Wirden, S Fourati, D Armenia, B Masquelier, L Fabeni, S Sayon, ...
Journal of antimicrobial chemotherapy 66 (7), 1481-1483, 2011
The system can't perform the operation now. Try again later.
Articles 1–20